
News from csimarket.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top csimarket.com News

Tokyo, Japan · TokyoTOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions…See the Story
LEQEMBI® IQLIK™(lecanemab-Irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Biogen (NASDAQ:BIIB)
50% Center coverage: 18 sources

Artificial Intelligence · San FranciscoSalesforce said on Monday its artificial intelligence platform "Agentforce 360" would be available globally across its suite of cloud-based tools to help clients automate routine tasks.Software firms are racing to enhance their products with advanced features as competition intensifies in an industry where clSee the Story
Salesforce Boosts AI Capabilities with Global Launch of Agentforce 360
100% Center coverage: 2 sources